Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Imke von Wasielewski"'
Autor:
Dirk Schadendorf, Carola Berking, Lisa Zimmer, Ralf Gutzmer, Alexander Kreuter, Andrea Forschner, Elisabeth Livingstone, Bastian Schilling, Selma Ugurel, Peter Mohr, Jessica Hassel, Patrick Terheyden, Henner Stege, Katharina Kaehler, Sebastian Haferkamp, Friedegund Meier, Claudia Pfoehler, Dirk Debus, Rudolf Herbst, Carmen Loquai, Frank Meiss, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Ulrike Leiter, Markus V Heppt, Michael Sachse, Fabian Ziller, Stephan Grabbe, Georg Lodde, Maximilian Haist, Friederike Rogall, Yuqi Tan, Kai Christian Klespe, Michael Tronnier, Imke von Wasielewski, Felix Kieker, Christopher Gebhardt, Jan Simon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/85987b665cf74916884422bf2059f401
Autor:
Dirk Schadendorf, Carola Berking, Jessica C Hassel, Lisa Zimmer, Ralf Gutzmer, Alexander Kreuter, Andrea Forschner, Bastian Schilling, Selma Ugurel, Katharina C Kähler, Peter Mohr, Patrick Terheyden, Felix Kiecker, Henner Stege, Sebastian Haferkamp, Friedegund Meier, Claudia Pfoehler, Dirk Debus, Rudolf Herbst, Carmen Loquai, Frank Meiss, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Axel Hauschild, Ulrike Leiter, Markus V Heppt, Christoffer Gebhardt, Michael Sachse, Fabian Ziller, Stephan Grabbe, Georg Lodde, Maximilian Haist, Friederike Rogall, Yuqi Tan, Imke von Wasielewski, Kai Christian Klespe, Michael Tronnier, Jan Christoph Simon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Adjuvant therapy with immune-checkpoint inhibitors (CPI) or BRAF/MEK-directed targeted therapy (TT) improves recurrence-free survival (RFS) for patients with advanced, BRAFV600-mutant (BRAFmut) resected melanoma. However, 40% of these pati
Externí odkaz:
https://doaj.org/article/b02d789393944e89a582fe64cc6e6ada
Autor:
Carola Berking, Elisabeth Livingstone, Dirk Debus, Carmen Loquai, Michael Weichenthal, Ulrike Leiter, Felix Kiecker, Peter Mohr, Thomas K. Eigentler, Janina Remy, Katharina Schober, Markus V. Heppt, Imke von Wasielewski, Dirk Schadendorf, Ralf Gutzmer
Publikováno v:
Cancers, Vol 15, Iss 18, p 4436 (2023)
Combined BRAF/MEK-inhibition constitutes a relevant treatment option for BRAF-mutated advanced melanoma. The prospective, non-interventional COMBI-r study assessed the effectiveness and tolerability of the BRAF-inhibitor dabrafenib combined with the
Externí odkaz:
https://doaj.org/article/d06b1c350906457c9e3a32544876fb20